GlassScriptPhysician profile
Anzhela Dvorkina
NPI 1023156049
$16,207.55
in general payments reported to CMS, 2019-2025
50 companies · $2,799 in 2025
The $2,799 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $2,045 · 2021: $2,018 · 2022: $2,101 · 2023: $2,527 · 2024: $2,909 · 2025: $2,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,194 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,194.21 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,881.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,530.69 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $1,526.92 | 2021-2025 | Ubrelvy, Qulipta, Viberzi |
| Novartis Pharmaceuticals Corporation | $1,239.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,206.78 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $1,135.35 | 2021-2025 | |
| Lilly USA, LLC | $1,014.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $883.39 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $638.72 | 2019-2025 | Ztlido |
| Abbott Laboratories | $512.41 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $484.19 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $464.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $433.61 | 2019-2023 | Verquvo |
| Amgen INC. | $310.31 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $301.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $238.97 | 2019-2025 | |
| Gilead Sciences, INC. | $232.63 | 2019-2025 | |
| Astellas Pharma US INC | $203.07 | 2023-2025 | Veozah, Myrbetriq |
| Ardelyx, INC. | $199.07 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $181.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Viiv Healthcare Company | $168.63 | 2024-2025 | Apretude |
| Esperion Therapeutics, INC. | $167.05 | 2024-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $153.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $116.42 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $110.50 | 2022-2025 | Rexulti |
| Horizon Therapeutics Plc | $92.68 | 2019-2020 | |
| Allergan, INC. | $85.34 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $74.70 | 2020-2022 | |
| Biogen, INC. | $71.94 | 2025 | Zurzuvae |
| Nestle Healthcare Nutrition INC. | $48.12 | 2020-2021 | |
| Ibsa Pharma INC. | $45.39 | 2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $43.40 | 2025 | Voquezna |
| Shield Therapeutics INC | $41.44 | 2024 | |
| Genentech USA, INC. | $37.02 | 2020-2021 | |
| Edwards Lifesciences Corporation | $28.57 | 2024 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $28.05 | 2020-2021 | |
| Nevro Corp. | $25.14 | 2022 | |
| Pharming Healthcare, INC. | $24.18 | 2025 | Ruconest |
| Grt US Holding, INC. | $23.79 | 2022 | |
| Eisai INC. | $23.61 | 2024 | |
| Sumitomo Pharma America, INC. | $21.84 | 2023 | Gemtesa |
| Vifor Pharma, INC. | $20.79 | 2025 | Veltassa |
| Agile Therapeutics, INC. | $19.66 | 2023 | Twirla |
| Metacel Pharmaceuticals LLC | $19.22 | 2025 | Ozobax |
| Advanced Oxygen Therapy INC. | $18.88 | 2024 | Topical Oxygen Chamber For Extremities |
| Optinose US, INC. | $16.78 | 2020 | |
| Hologic Sales and Service, LLC | $16.23 | 2021 | |
| Phadia US INC. | $15.38 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anzhela Dvorkina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.